Delisting risk
Satellos Bioscience
Developing SAT-3247, an oral muscle-repair therapy for Duchenne muscular dystrophy.
$8.83
After-hours close−0.05 (−0.62%)
At close$8.89(−7.54%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.59 | — | — |
| Aug 2026 | −$0.51 | −$0.56 | −9.7% |
| May 2026 | −$0.51 | −$0.53 | −3.9% |
| Mar 2026 | −$0.36 | −$0.47 | −30.6% |
| Nov 2025 | −$0.33 | −$0.36 | −11.1% |
The latest year is open to everyone — the 7 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | −$0.59 | — | — | — | — | — |
| Aug 13, 2026 | −$0.51 | −$0.56 | −9.7% | — | — | — |
| May 14, 2026 | −$0.51 | −$0.53 | −3.9% | — | — | — |
| Mar 27, 2026 | −$0.36 | −$0.47 | −30.6% | — | — | — |
| Nov 14, 2025 | −$0.33 | −$0.36 | −11.1% | — | — | — |
The latest year is open to everyone — the 7 quarters behind it read with an account. Sign in | ||||||
| Aug 13, 2025 | ||||||
| May 13, 2025 | ||||||
| Mar 26, 2025 | ||||||
| Nov 13, 2024 | ||||||
| Aug 12, 2024 | ||||||
| May 14, 2024 | ||||||
| Mar 27, 2024 | ||||||